In my two previous articles, I have talked about Computational Biology as a field, its advancements, and then about its market and investment. Computational biology is rapidly growing and evolving every single day. New technologies, uses, and practices are developing at a faster and faster rate. Computational biology allows us to utilize and apply computational methods, to analyze vast amounts of biological and genetic data. This allows scientists to draw parallels and analyze vast amounts of biological matter. This field is growing in its relevance, and the field of computational biology is only set to grow, due to the vast demand for computational biology majors, as healthcare and research institutions place a greater emphasis on this already growing and important field. This means that as investors, there is great potential.
Publicly Traded Biotech Companies With Computational Biology Applications:
Using computational biology, in specific applications such as drug discovery is a valuable application, and has multiple advantages. Accelerated target identification, optimized small molecules, biologics design, better clinical trials, and more. This can also drastically decrease R&D costs, and tasks like drug repurposing, novel target identification, optimizing for the complex nets of molecular pathways, and simulation of a molecule’s toxicity in a human body. Companies that embrace these technologies are pioneers and will be full of value and growth. Here are some examples of companies that follow/keep in mind the rhetoric described.
- BenevolentAI SA (AMS: BAI): Drug maker that uses computational tools that use predictive AI algorithms to analyze data more efficiently.
- BioXcel Therapeutics Inc (NASDAQ: BTAI): Drug developer that uses AI to identify drug candidates across immunology and neuroscience.
- Lantern Pharma Inc. (NASDAQ: LTRN): Specializes in making precision oncology therapies, such as developing precision cancer drugs.
- Exscientia PLC (NASDAQ: EXAI): Oxford-based clinical stage research firm that focuses on drug discovery for small molecules. IPO’d in October 2021 for $510.4M
- AbCellera Biologics Inc (NASDAQ: ABCL): Vancouver-based biotech company that tries to develop antibody therapeutics using AI. Company IPO’d for $555.5M.
- Recursion Pharmaceuticals Inc (NASDAQ: RXRX): Utah-based clinical-stage company that uses machine learning techniques to expedite drug delivery.
This promising field is sure to accelerate research, through its automation of data analysis and high-impact data processing. Lots of money and investment are sure to be poured into this value-filled industry. Questions previously unthinkable can be cracked. Optimization of various practices related to biology will emerge and improve. Computational biology will continue to be an essential tool to unlock the secrets of life.